Beyond Meat Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Beyond Meat Inc trades at $0.41 (market cap $215.41M), while Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 2.3× Beyond Meat Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| BYND | DNA | |
|---|---|---|
Market Cap | $215.41M | $505.73M |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $16.14 |
52-Week Low | $0.42 | $5.48 |
Enterprise Value | $455.69M | $607.68M |
Signals from Pluang's Aura AI — not financial advice
Beyond Meat (BYND) trades at $0.4066, down 21.81% amid a 1-for-30 reverse stock split announcement. The stock is technically bearish with negative cash flow from operations, though recent quarters show mixed earnings beats. Revenue has declined from $419M in 2022 to $275M in 2025, but net income turned positive at $178M in 2025, driven by a one-time gain. Analyst sentiment is heavily skewed toward sell ratings, reflecting skepticism about the company's turnaround efforts and persistent cash burn.
The outlook remains challenging due to declining sales, high cash burn, and weak investor confidence. While valuation ratios like P/S of 0.61 appear low, the risk of further dilution or delisting outweighs potential upside. Key risks include execution missteps and competitive pressure in the plant-based food sector.
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →